Gossamer Bio Inc. (GOSS) Tops Q3 EPS by 5c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq end lower on semiconductor selloff as AI spending concerns mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Gossamer Bio Announces Third Quarter 2020 Financial Results and Provides Corporate Update
November 10, 2020 4:01 PM EST- GB004: SHIFT-UC Phase 2 trial enrolling patients with active ulcerative colitis (UC) -
- GB002: TORREY Phase 2 trial activated in patients with pulmonary arterial hypertension (PAH) -
- GB1275: Two posters with data from ongoing Phase 1/2 KEYNOTE-A36 clinical trial in advanced solid tumors presented at Society for Immunotherapy of Cancer Meeting 2020 -
- GB001: Engaging with global regulatory authorities about forward clinical development path for an oral DP2 antagonist in moderate-to-severe asthma -
- Cash, cash equivalents and marketable securities totaled $555... More
